Induction of apoptosis by Xiakemycin A in human hepatoma HepG2 cells.
Annexin A5
/ metabolism
Antineoplastic Agents
/ pharmacology
Apoptosis
/ drug effects
Carcinoma, Hepatocellular
/ drug therapy
Caspase 3
/ metabolism
Caspase 9
/ metabolism
DNA Damage
/ drug effects
Dose-Response Relationship, Drug
Hep G2 Cells
Humans
Membrane Potentials
/ drug effects
Mitochondria, Liver
/ physiology
Naphthoquinones
/ pharmacology
Poly (ADP-Ribose) Polymerase-1
/ metabolism
Propidium
/ metabolism
Reactive Oxygen Species
/ metabolism
Journal
Medicine
ISSN: 1536-5964
Titre abrégé: Medicine (Baltimore)
Pays: United States
ID NLM: 2985248R
Informations de publication
Date de publication:
Apr 2020
Apr 2020
Historique:
entrez:
26
4
2020
pubmed:
26
4
2020
medline:
10
5
2020
Statut:
ppublish
Résumé
Xiakemycin A (XKA), a new antibiotic in the pyranonaphthoquinone family, shows antitumor activity. However, the type of cell death induced by XKA remains elusive. In this study, we aim to investigate the type of death induced by XKA in hepatic cancer.The apoptotic features, such as chromatic agglutination, reactive oxygen species generation and membrane potential of mitochondria, in HepG2 cells treated by XKA were measured by Hoechst 33342 staining and flow cytometry. Apoptosis of HepG2 cells treated with XKA was determined by Annexin V-FITC/propidium iodide double staining and Western blot analysis, respectively.XKA had a significant dose-dependent elevation of chromatic agglutination, reactive oxygen species generation, Annexin V and propidium iodide staining, decrease of membrane potential. Meanwhile, in apoptotic HepG2 cells induced by XKA, robust increment was noticed in p53 expression, cleavage of PARP, caspase-3, and caspase-9.XKA showed potent inhibitory effects on the proliferation of HepG2 cells. Such phenomenon may be related to activation of the apoptotic pathway.
Identifiants
pubmed: 32332640
doi: 10.1097/MD.0000000000019848
pii: 00005792-202004240-00051
pmc: PMC7220762
doi:
Substances chimiques
Annexin A5
0
Antineoplastic Agents
0
Naphthoquinones
0
Reactive Oxygen Species
0
xiakemycin A
0
Propidium
36015-30-2
PARP1 protein, human
EC 2.4.2.30
Poly (ADP-Ribose) Polymerase-1
EC 2.4.2.30
CASP3 protein, human
EC 3.4.22.-
CASP9 protein, human
EC 3.4.22.-
Caspase 3
EC 3.4.22.-
Caspase 9
EC 3.4.22.-
Types de publication
Journal Article
Observational Study
Langues
eng
Sous-ensembles de citation
IM
Pagination
e19848Références
Expert Opin Med Diagn. 2008 Sep;2(9):1013-24
pubmed: 23495923
World J Gastroenterol. 2008 Dec 28;14(48):7321-8
pubmed: 19109865
J Exp Clin Cancer Res. 2011 Sep 26;30:87
pubmed: 21943236
J Antibiot (Tokyo). 2015 Dec;68(12):771-4
pubmed: 26104142
J Vis Exp. 2011 May 23;(51):
pubmed: 21654619
Oncol Rep. 2018 Jun;39(6):3048-3054
pubmed: 29693151
Annu Rev Genet. 2009;43:95-118
pubmed: 19659442
Int J Biochem Cell Biol. 2000 Feb;32(2):157-70
pubmed: 10687951
Dose Response. 2006 May 01;3(3):425-42
pubmed: 18648617
Basic Res Cardiol. 2007 Nov;102(6):542-52
pubmed: 17891523
Bioorg Med Chem. 2009 Oct 15;17(20):7131-7
pubmed: 19783445
Biochem Pharmacol. 2000 Nov 1;60(9):1367-79
pubmed: 11008131
Cold Spring Harb Protoc. 2011 Jan 01;2011(1):pdb.prot5557
pubmed: 21205857
Neoplasia. 2000 May-Jun;2(3):208-25
pubmed: 10935507
ISRN Oncol. 2012;2012:137289
pubmed: 23119185
Cancer Res. 2010 Oct 1;70(19):7684-9
pubmed: 20841468
Cancer Cell. 2014 Mar 17;25(3):304-17
pubmed: 24651012